IFNG and graft versus host disease: For example, if MSCs are administered too early before disease onset (such as in GvHD) [41,42,43], or if signals required for their immunomodulation (such as NFκB, TNF-α receptor, or IFN-γ) [41,44] are blocked, MSCs lose their protective effects.